Pyxis Oncology (PYXS) Return on Sales (2024 - 2026)
Pyxis Oncology (PYXS) posted quarterly Return on Sales of 0.02% for Q4 2025, up 4.0% year-over-year from 0.02% in Q4 2024, and up 95.23% quarter-over-quarter from 0.35% in Q3 2025.
Pyxis Oncology (PYXS) Return on Sales (2024 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Return on Sales for 2 consecutive years, with 0.02% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Sales rose 4.0% year-over-year to 0.02%; the TTM figure through Dec 2025 stood at 0.06% (down 1.0% YoY), while the FY2025 annual figure was 0.06%, down 1.0% from the prior year.
- Return on Sales climbed to 0.02% in Q4 2025 per PYXS's latest filing, from 0.35% in the prior quarter.
- Across five years, Return on Sales topped out at 0.01% in Q1 2024 and bottomed at 0.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.00% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.00% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.00% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.00% |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | -0.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.05% |
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -0.35% |
| Jun 30, 2025 | -0.07% |
| Dec 31, 2024 | -0.05% |
| Mar 31, 2024 | -0.01% |